Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.05.2026 | Series A | $82.6M | - |
Mentions in press and media 3
| Date | Title | Description |
| 05.05.2026 | Cytospire Therapeutics Raises £61M in Series A Funding | Cytospire Therapeutics, a London, UK-based biotech company developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s own immune system, raised £61M in Series A funding.
... |
| 05.05.2026 | Cytospire Secures £61M Series A to Advance Cancer Drugs | Cytospire Therapeutics has completed a £61 million ($83 million) Series A funding round. The capital will be used to advance Cytospire’s innovative “pan-gamma delta” T-cell engager platform into first-in-man clinical trials in a selection o... |
| - | Cytospire Therapeutics | “Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.” |
Reviews 0
